Vandetanib and the management of advanced medullary thyroid cancer

Michael Campbell, Carolyn D. Seib, Jessica Gosnell

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

PURPOSE OF REVIEW: Vandetanib is a small molecule tyrosine kinase inhibitor that has been recently approved as an 'orphan drug' for the treatment of patients with unresectable, locally advanced, or metastatic medullary thyroid cancer (MTC). RECENT FINDINGS: MTC is a neuroendocrine malignancy frequently associated with mutations to the RET proto-oncogene. Vandetanib selectively targets RET, vascular endothelial growth factor receptor-2, and epidermal growth factor receptor dependent signaling. Vandetanib has been shown to improve progression-free survival in patients with advanced MTC. In general, vandetanib is well tolerated, but QTc prolongation remains a potential concern demanding careful patient selection and monitoring. SUMMARY: Vandetanib has emerged as one of the more promising small molecule tyrosinse kinase inhibitors, providing durable rates of disease stabilization, with an acceptable adverse event profile in patients with advanced MTC.

Original languageEnglish (US)
Pages (from-to)39-43
Number of pages5
JournalCurrent Opinion in Oncology
Volume25
Issue number1
DOIs
StatePublished - Jan 2013

Fingerprint

Orphan Drug Production
Vascular Endothelial Growth Factor Receptor-2
Proto-Oncogenes
Physiologic Monitoring
Epidermal Growth Factor Receptor
Protein-Tyrosine Kinases
Patient Selection
Disease-Free Survival
Phosphotransferases
N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine
Medullary Thyroid cancer
Mutation
Neoplasms
Therapeutics

Keywords

  • Medullary thyroid cancer
  • Tyrosine kinase inhibitor
  • Vandetanib

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Vandetanib and the management of advanced medullary thyroid cancer. / Campbell, Michael; Seib, Carolyn D.; Gosnell, Jessica.

In: Current Opinion in Oncology, Vol. 25, No. 1, 01.2013, p. 39-43.

Research output: Contribution to journalArticle

Campbell, Michael ; Seib, Carolyn D. ; Gosnell, Jessica. / Vandetanib and the management of advanced medullary thyroid cancer. In: Current Opinion in Oncology. 2013 ; Vol. 25, No. 1. pp. 39-43.
@article{ebcc1ae04f72451288b40602622b42d7,
title = "Vandetanib and the management of advanced medullary thyroid cancer",
abstract = "PURPOSE OF REVIEW: Vandetanib is a small molecule tyrosine kinase inhibitor that has been recently approved as an 'orphan drug' for the treatment of patients with unresectable, locally advanced, or metastatic medullary thyroid cancer (MTC). RECENT FINDINGS: MTC is a neuroendocrine malignancy frequently associated with mutations to the RET proto-oncogene. Vandetanib selectively targets RET, vascular endothelial growth factor receptor-2, and epidermal growth factor receptor dependent signaling. Vandetanib has been shown to improve progression-free survival in patients with advanced MTC. In general, vandetanib is well tolerated, but QTc prolongation remains a potential concern demanding careful patient selection and monitoring. SUMMARY: Vandetanib has emerged as one of the more promising small molecule tyrosinse kinase inhibitors, providing durable rates of disease stabilization, with an acceptable adverse event profile in patients with advanced MTC.",
keywords = "Medullary thyroid cancer, Tyrosine kinase inhibitor, Vandetanib",
author = "Michael Campbell and Seib, {Carolyn D.} and Jessica Gosnell",
year = "2013",
month = "1",
doi = "10.1097/CCO.0b013e32835a42b9",
language = "English (US)",
volume = "25",
pages = "39--43",
journal = "Current Opinion in Oncology",
issn = "1040-8746",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Vandetanib and the management of advanced medullary thyroid cancer

AU - Campbell, Michael

AU - Seib, Carolyn D.

AU - Gosnell, Jessica

PY - 2013/1

Y1 - 2013/1

N2 - PURPOSE OF REVIEW: Vandetanib is a small molecule tyrosine kinase inhibitor that has been recently approved as an 'orphan drug' for the treatment of patients with unresectable, locally advanced, or metastatic medullary thyroid cancer (MTC). RECENT FINDINGS: MTC is a neuroendocrine malignancy frequently associated with mutations to the RET proto-oncogene. Vandetanib selectively targets RET, vascular endothelial growth factor receptor-2, and epidermal growth factor receptor dependent signaling. Vandetanib has been shown to improve progression-free survival in patients with advanced MTC. In general, vandetanib is well tolerated, but QTc prolongation remains a potential concern demanding careful patient selection and monitoring. SUMMARY: Vandetanib has emerged as one of the more promising small molecule tyrosinse kinase inhibitors, providing durable rates of disease stabilization, with an acceptable adverse event profile in patients with advanced MTC.

AB - PURPOSE OF REVIEW: Vandetanib is a small molecule tyrosine kinase inhibitor that has been recently approved as an 'orphan drug' for the treatment of patients with unresectable, locally advanced, or metastatic medullary thyroid cancer (MTC). RECENT FINDINGS: MTC is a neuroendocrine malignancy frequently associated with mutations to the RET proto-oncogene. Vandetanib selectively targets RET, vascular endothelial growth factor receptor-2, and epidermal growth factor receptor dependent signaling. Vandetanib has been shown to improve progression-free survival in patients with advanced MTC. In general, vandetanib is well tolerated, but QTc prolongation remains a potential concern demanding careful patient selection and monitoring. SUMMARY: Vandetanib has emerged as one of the more promising small molecule tyrosinse kinase inhibitors, providing durable rates of disease stabilization, with an acceptable adverse event profile in patients with advanced MTC.

KW - Medullary thyroid cancer

KW - Tyrosine kinase inhibitor

KW - Vandetanib

UR - http://www.scopus.com/inward/record.url?scp=84871948951&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871948951&partnerID=8YFLogxK

U2 - 10.1097/CCO.0b013e32835a42b9

DO - 10.1097/CCO.0b013e32835a42b9

M3 - Article

VL - 25

SP - 39

EP - 43

JO - Current Opinion in Oncology

JF - Current Opinion in Oncology

SN - 1040-8746

IS - 1

ER -